| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Shareholders Have the Information They Need to Make an Informed Vote
Preliminary Net Sales Results for Third Quarter Underscore a Positive Trajectory
Continues to Oppose the Proposed Merger and Will Vote AGAINST at the Special Meeting
Yunqi Capital Limited (together with its affiliates and the funds it advises, "Yunqi Capital"), an investment management firm and 5.1% shareholder of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ:STAA), today issued the following letter to the Board of Directors of STAAR regarding Yunqi's opposition to the proposed sale to Alcon Inc. (SIX/NYSE:ALC) on the terms announced on August 5, 2025.
The text of the letter to the Board is as follows:
October 21, 2025
STAAR Surgical Company
25510 Commercentre Drive
Lake Forest, CA 92630
Dear Members of the Board:
We are writing to express concern over recent representations by the Company regarding the proposed merger with Alcon, to urge you to hold the special meeting of shareholders on October 23, 2025, as planned, and to reiterate our confidence in the future of the Company after the shareholder vote on the proposed merger is concluded and presumably defeated. We continue to oppose the proposed merger and have accordingly voted our shares against it.
